The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimerâ€™s disease phenotype by Yash B. Joshi & Domenico PraticÃ²
CELLULAR NEUROSCIENCE
REVIEW ARTICLE
published: 14 January 2015
doi: 10.3389/fncel.2014.00436
The 5-lipoxygenase pathway: oxidative and inflammatory
contributions to the Alzheimer’s disease phenotype
Yash B. Joshi and Domenico Praticò*
Department of Pharmacology and Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA, USA
Edited by:
Victoria Campos, Instituto Nacional
de Neurologia y Neurocirugia,
Mexico
Reviewed by:
Muzamil Ahmad, Indian Institute of
Integrative Medicine, India
Luigi Iuliano, Sapienza University of
Rome, Italy
*Correspondence:
Domenico Praticò, Department of
Pharmacology and Center for
Translational Medicine, Temple
University School of Medicine, 947
Medical Education and Research
Building, 3500 North Broad Street,
Philadelphia, PA 19140, USA
e-mail: praticod@temple.edu
Alzheimer’s disease (AD) is the most common, and, arguably, one of the most-well
studied, neurodegenerative conditions. Several decades of investigation have revealed
that amyloid-β and tau proteins are critical pathological players in this condition. Genetic
analyses have revealed specific mutations in the cellular machinery that produces
amyloid-β, but these mutations are found in only a small fraction of patients with the early-
onset variant of AD. In addition to development of amyloid-β and tau pathology, oxidative
damage and inflammation are consistently found in the brains of these patients. The 5-
lipoxygenase protein enzyme (5LO) and its downstream leukotriene metabolites have long
been known to be important modulators of oxidation and inflammation in other disease
states. Recent in vivo evidence using murine knock-out models has implicated the 5LO
pathway, which also requires the 5LO activating protein (FLAP), in the molecular pathology
of AD, including the metabolism of amyloid-β and tau. In this manuscript, we will provide
an overview of 5LO and FLAP, discussing their involvement in biochemical pathways
relevant to AD pathogenesis. We will also discuss how the 5LO pathway contributes to the
molecular and behavioral insults seen in AD and provide an assessment of how targeting
these proteins could lead to therapeutics relevant not only for AD, but also other related
neurodegenerative conditions.
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ALZHEIMER’s DISEASE: BACKGROUND
Alzheimer’s disease (AD) is the most common aging-associated
neurodegenerative condition with dementia, marked by profound
and irreversible memory impairment and cognitive deficits. The
total number of individuals with AD worldwide is estimated to
be over 35 million with a predicted estimated annual economic
burden of $600 billion USD (Alzheimer’s Association, 2014). The
vast majority of AD cases are sporadic, without a clear genetic
component, and symptoms of AD typically declare themselves
after the age of 65, with 11% of those 65 and older and 32% of 85
and older showing signs of AD (source: Alzheimer’s Association).
Current population demographics suggest that those aged 65 and
older will increase from 13% now to 20% of total population
in 2030, making the future burden of AD a tremendous public
health challenge. In stark contrast to the looming public health
challenge of AD, current therapeutic options for AD are limited.
Although a plethora of agents are currently being investigated
in phase II and phase III trials, currently approved medications
include several acetylcholinesterase inhibitors and N-methyl D-
aspartate (NMDA) antagonists, which do little to modify dis-
ease course (Caraci et al., 2013; Tan et al., 2014). Given the
confluence of an increased burden of AD in the near-future to
health systems globally and a lack of approved therapeutic targets,
investigation of targets that address multiple different facets of
AD pathophysiology must be actively sought to help address this
problem. Below we will give an overview of some of the molecular
insults associated with AD, and discuss how the 5-lipoxygenase
(5LO) enzyme presents a novel molecular pathway that is an
attractive target for AD therapy.
Aβ AND tau IN ALZHEIMER’s DISEASE
Through extensive clinical and molecular work over the past
several decades, the biochemical pathways that lead to AD
pathology have been well characterized. The cardinal patholo-
gies observed in AD are the extracellular deposits of amyloid-β
protein (Aβ) known as Aβ plaques, and intracellular accumu-
lations of the hyperphosphorylated microtubule-associated tau
protein known as neurofibrillary tangles (Iqbal et al., 2010;
Holtzman et al., 2011). Current dogma presumes Aβ as the
upstream molecular initiator in AD based on evidence that
mutations in the Aβ precursor protein (APP) and presenilins,
main components of the pathways that cleave it to produce
Aβ peptides, are found in early-onset, familial variants of AD.
Additionally, patients with Down’s syndrome, in which there
is an additional chromosome 21, the locus of the APP gene,
have significantly increased rates of AD when compared with
the general population (Wilcock and Griffin, 2013). However,
more recent clinical data have also found mutations in the APP
gene that are protective and reduce AD risk (Jonsson et al., 2012,
2013).
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Amyloid-β peptide is formed by the sequential cleavage of
APP by the β-secretase (β APP cleavage enzyme, BACE 1) and the
γ-secretase complex (composed of the nicastrin, presenillin, PS1),
anterior-pharynx defective-1 protein [APH-1], and presenillin
enhancer protein [Pen-2], as shown in Figure 1. While APP may
be cleaved by α-secretase and then γ-secretase to produce non-
amyloidogenic products, the Aβ producing pathway is thought
to be priviledged in AD. Generation of higher amounts and
subsequent aggregation of Aβ peptide through the sequential β-
and γ-secretase cleavages is thought to lead to soluble oligomers,
followed by longer fibrils, and finally insoluble plaques, which are
found abundantly in the vast majority of AD patients on autopsy.
Although insoluble plaques have been found in the brains of
patients without AD, current thinking is that low-n Aβ oligomers
perpetuate the brunt of molecular insults in AD rather than
insoluble plaques per se (Ono and Yamada, 2011).
The hyperphosphorylation of the microtubule-associated tau
protein also contributes to the molecular damage in AD. Tau is
thought to be important in neuronal ultrastructure and axonal
transport, both critical to overall neuron function and signaling
(Iqbal et al., 2010). Upon hyperphosphorylation, tau loses affinity
for microtubules, dissociating from them, and begins to aggre-
gate, eventually precipitating inside neuronal cells, as shown in
Figure 2. While Aβ is hypothesized to be the initiating event, cor-
tical burden of neurofibrillary tau tangles correlates with demen-
tia severity much more robustly (Oddo et al., 2006; Nelson et al.,
FIGURE 1 | APP metabolism in Alzheimer’s disease (AD). Amyloid β
precursor protein (APP) is synthesized in the endoplasmic reticulum and
transported to the cell surface through endosomes via the trans-Golgi
network. At the cell membrane, APP may undergo either
non-amyloidogenic processing or pro-amyloidogenic processing. If APP
undergoes non-amyloidogenic processing, it is first cleaved by the
α-secretase, and then the γ-secretase to produce p3 peptide, which does
not form amyloid deposits. If APP is cleaved by β-, and then γ-secretase
(composed of nicastrin, presenilin 1 [PS1], anterior pharynx defective-1
protein [APH-1], and presenilin enhancer 2 [PEN2]), then Aβ peptides are
produced. Amyloid-β peptides form oligomers, and then fibrils, which
become insoluble, and eventually deposit into Aβ plaques. While initially it
was thought that Aβ plaques were the causal pathology in AD, soluble
low-n oligomers are currently thought to play the initiating role in synaptic
dysfunction and neuronal cell death.
2007). Normal tau protein phosphorylation status is generally
thought to be maintained by the relative balance of tau-specific
kinases(s), which would add phosphate, and phosphatase(s),
which would remove phosphate. At present, cyclin-dependent
kinase 5 and glycogen synthase kinase 3 beta represent two such
tau kinases that have been found to be abnormally functional in
the brains of AD patients, and therefore of functional importance
(Hanger et al., 1992; Baumann et al., 1993; Pei et al., 1999).
Although the specific mechanisms from disruption of normal
functioning of both Aβ and tau to AD symptomatology remains
unclear, both have been associated with oxidative stress and
inflammation found in the brains of AD patients.
OXIDATIVE STRESS AND INFLAMMATION IN ALZHEIMER’s
DISEASE
Balance of oxidation and reduction is critical to appropriate
cellar function and results from the interplay of mechanisms
that produce pro-oxidant molecules and those processes that
detoxify them. The brain receives an overwhelming proportion
of total body blood flow (i.e., oxygen) and glucose when adjusted
for its weight, and in neurons, this relatively high oxygen and
glucose requirement is directed towards energy generation (i.e.,
ATP production) and oxidative phosphorylation in mitochondria
(Scheinberg and Stead, 1949; Smith et al., 2007). The vast majority
of oxidative species (predominantly reactive oxygen species such
as superoxide anions, hydroxyl radicals and hydrogen peroxide)
produced by this metabolism is detoxified by antioxidant vitamins
(e.g., vitamin C, and E) as well as superoxide dismutase, catalase
and glutathione peroxidase (Adibhatla and Hatcher, 2010). A
basal level of oxidants contributes to appropriate cellular signaling
and modulates cell function but elevated levels of reactive oxygen
species leads to oxidation and irreversible modification of
proteins, lipids and nucleic acids which ultimately result in
the disruption of their regular function (Ray et al., 2012).
Interestingly, consistent evidence supports the hypothesis that a
progressive accumulation of oxidative stress damage to important
cellular molecules is a fundamental mechanism involved in the
process of aging, which is the strongest risk factor for developing
sporadic AD (Jacob et al., 2013).
In AD, oxidative modifications of proteins, lipids, DNA in
the brain have been repeatedly found. Thus several studies
have shown the presence of DNA and RNA oxidation products
such as 8-oxo-2′-deoxyguanosine (8-oxo-dG) and 8-dihydro-2′-
guanosine (8OH) in AD brains, and lipid peroxidation products
such as F2-isoprostanes and various reactive aldehydes have been
reported in not only in AD brains but also in patient cerebrospinal
fluid of patients with a clinical diagnosis of AD (de Leon et al.,
2007; Sutherland et al., 2013). Although the precise mechanism
of oxidation stress in AD remains elusive, the sulfur atom of
methionine 35 in Aβ peptide has been shown to produce free
radicals (Butterfield et al., 2013). Replacement of methionine to
cysteine reduced oxidative damage in model organisms such as
C. elegans, and substitution of sulfur with a methylene moiety
reduces oxidation in vitro of the Aβ peptide (Yatin et al., 1999;
Dai et al., 2007). Although clinical trials have not yet found a
meaningful disease-modifying effect of antioxidant agents in the
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FIGURE 2 | Tau phosphorylation in AD. In the brains of aged, disease-free
control subjects, tau is associated with, and has affinity for microtubules,
stabilizing them, and promoting normal axonal functioning. Tau may be
phosphorylated and de-phosphorylated, with phosphorylation altering its
microtubule affinity and stabilizing function, and this is maintained through an
interplay of tau-associated kinases and phosphatases. In the brains of AD
subjects, tau becomes hyperphosphorylated by means of relatively greater
net tau kinase activity/reduced phosphatase activity. Hyperphosphorylated
tau has a much lower affinity for microtubules, resulting in disruption of
appropriate microtubule structure. Additionally hyperphosphorylated tau
aggregates together, eventually generating insoluble tau species which
eventually form neurofibrillary tangles intracellularly. As a result of
neurofibrillary tangle formation, cellular trafficking and transport is perturbed,
leading to cell death and synaptic dysfunction.
treatment of AD, many studies have founds significant association
between diets rich in antioxidants and lower risk of AD-risk
(Pocernich et al., 2011).
Besides oxidative stress damage, altered inflammatory reac-
tions are strongly associated with AD pathology and cogni-
tive dysfunction. The dysregulation of inflammatory cytokines
as well as immune cells (i.e., microglia and astrocytes) activa-
tion in AD brains has been well-documented. Microglia have
some ability to clear Aβ, but are unable to effectively phago-
cytate high concentrations (or insoluble conformations) of it
resulting in aberrantly activated microglia that associate with
both Aβ plaques and neurofibrillary tangles (Hickman et al.,
2008; Johnston et al., 2011; D’Andrea et al., 2004; Krabbe
et al., 2013; Morales et al., 2013). Astrocytes can be directly
stimulated by Aβ to secrete pro-inflammatory molecules, and
evidence is growing that they have the ability to produce Aβ
peptides themselves (Blasko et al., 2000; Wang et al., 2011a;
Jo et al., 2014). Microgliosis and astrocytosis follow deposi-
tion of Aβ plaques and neurofibrillary tangles as shown by
immunohistochemistry, and have been shown to precede neu-
ronal loss (Sheng et al., 1997a,b; Sheffield et al., 2000; Wright
et al., 2013). Resulting directly from immune cell activation,
AD brains also have higher tissue levels of cytokines, including
various interleukins (IL) such as IL-1β, tumor necrosis factor
α (TNFα), and interferon γ (IFNγ), all independently-linked to
increased production of Aβ and tau phosphorylation (Zilka et al.,
2012).
Despite this compelling evidence, prospective clinical trials
targeting oxidative stress and inflammation have previously not
found clear and incontrovertible disease-modifying effects on the
progression of AD. With regard to oxidation, the largest prospec-
tive clinical trials have tested combinations of the monoamine
oxidase inhibitor, selegiline and alpha-tocopherol (i.e., vitamin E)
or the cholinesterase inhibitor, donepezil and alpha-tocopherol,
either in patients with severe disease or in the prodromal stage,
in those with mild cognitive impairment (Sano et al., 1997;
Petersen et al., 2005). In these studies, no difference was found
between antioxidant-treated groups and controls in terms of
disease progression or on cognitive assessment at the end of
intervention. Other studies using a variety of antioxidants such
as resveratrol and curcumin, among others, have noted either no
benefit, or benefit with limited effect sizes in small cohorts (for
an excellent review see Mecocci and Polidori, 2012). Recently,
the Trial of Vitamin E and Memantine in Alzheimer’s Dis-
ease (TEAM-AD) has reported reduction in functional cognitive
decline in those receiving alpha-tocopherol compared to placebo
(Dysken et al., 2014). However, these results have been criti-
cized due to the relatively high dose of vitamin E used, and
the fact memantine alone or in combination with vitamin E
did not produce similar protective effects (Corbett and Ballard,
2014).
The earliest anti-inflammatory strategies in AD resulted
from data showing reduced AD incidence in patients with
rheumatoid arthritis, who have a high exposure to non-steroidal
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anti-inflammatory agents (McGeer and Rogers, 1992; Stewart
et al., 1997). This finding was reproduced in many population
studies (for a review, see McGeer and McGeer, 2013). However,
placebo-controlled trials for AD using anti-inflammatory agents
showed little benefit and significant adverse effects leading to
subject dropout, although it is to be noted that the majority
of these trials used a relatively short treatment window before
trial termination or cessation (McGeer et al., 1996). Despite
these trial failures, new data indicating mutations in Triggering
receptor expressed on myeloid cells 2 gene (TREM2), which
encodes a membrane protein found on immune cells, confers
significant risk in the development of AD, has reinvigorated
interest in an anti-inflammatory strategy in AD (Jonsson et al.,
2013).
In recent years, mounting evidence has indicated that Aβ
and tau pathologies begin depositing and impair neuronal func-
tion long before symptoms are manifest. Give this insight it is
unlikely that recent and previously conducted clinical trials can
adequately address the true effectiveness of anti-oxidant and anti-
inflammatory agents. Additionally, the multifactorial nature of
the molecular insults in AD make it likely that a strategy that
addresses not only pathological Aβ and tau accumulation, but
also oxidation and inflammation would have the best chance of
success.
THE 5-LIPOXYGENASE PATHWAY
The 5LO inserts molecular oxygen into the 5th carbon of free
or esterified fatty acids, most notably arachidonic acid. In order
to carry out the reaction, 5LO also requires 5LO activating
protein, FLAP, which presents the substrate for enzymatic
action (for a complete review on 5LO biology, see Rådmark and
Samuelsson, 2010). Immediate products of 5LO include unstable
5-hydroperoxyeicosatetraenoic acid which is either reduced
to 5-hydroxyeicosatetraenoic acid or leukotriene A4 (LTA4).
Depending on the cellular milieu, LTA4 can be metabolized either
to leukotriene B4 or C4 (LTB4 or LTC4), with LTC4 further being
metabolized to LTD4 and LTE4 (Bishayee and Khuda-Bukhsh,
2013), as shown in Figure 3.
5-lipoxygenase is found in vasculature, in endothelial cells, as
well as throughout the central nervous system, in both neuron
and glia (Chu and Praticò, 2009). Interestingly, 5LO expression
and its metabolites increase with age in both animal models
as well as human subjects. 5-lipoxygenase protein levels are
particularly enriched in both cortex as well as hippocampus,
areas known to be particularly vulnerable in neurodegeneration,
and in AD in particular (Lammers et al., 1996; Chinnici et al.,
2007). 5-lipoxygenase promotes lipid peroxidation in vitro as well
as in brain tissue (Czubowicz et al., 2010; Czapski et al., 2012).
Leukotrienes, metabolic products of 5LO activation, initiate
immune cell chemotaxis and are critical molecular players in the
inflammatory pathophysiology of asthma and allergy (Kanaoka
and Boyce, 2014).
5LO, FLAP AND THE ALZHEIMER’s DISEASE PHENOTYPE
Post-mortem studies have initially shown that 5LO is increased
in AD (Firuzi et al., 2008; Ikonomovic et al., 2008). A small
pilot study in humans has linked 5LO gene polymorphisms to
FIGURE 3 | The 5-lipoxygenase pathway. The 5-lipoxygenase protein
(5LO) inserts molecular oxygen into free and esterified fatty acids with the
aid of 5-lipoxygenase activating protein (FLAP). 5-lipoxygenase acts on
arachidonic acid to produce 5-HPETE, which is metabolized into 5-HETE or
leukotriene A4, depending on the cellular milieu. Leukotriene A4 is then
either acted on by LTA4 hydrolase to produce LTB4 or by LTC4 synthase to
produce LTC4. Leukotriene B4 may then act on leukotriene B4 receptors
(BLT1, BLT2) which are G-protein coupled receptors (GPCRs) to initiate
second messenger systems and produce cellular effects. Leukotriene C4
may be acted on by γ-glutamyltransferase 1 to produce LTD4, which may be
acted on by LTD4 dipeptidase to yield LTE4. Collectively LTC4, LTD4, and
LTE4 are known as the cysteinyl leukotrienes. These cysteinyl leukotrienes
all may act on cysteinyl leukotriene receptors (CysLT1, CysLT2) which are
also GPCRs to exert downstream effects. Collectively, leukotriene receptor
activation is known to modulate chemokine production, immune cell
activation and inflammation.
early- and late-onset AD, although large-scale population studies
are yet to confirm these findings (Qu et al., 2001). In neuro2A
cells harboring the Swedish APP mutation, knockout of 5LO
reduces reduces their ability to produce and release soluble Aβ
levels (Chu and Praticò, 2011a). This effect is due to reduced
activity of γ-secretase, with 5LO knockout lowering steady-state
expression of nicastrin, PS1, APH-1 and Pen-2 proteins with-
out affecting either APP, the β-secretase or α-secretase pathway.
On the other hand, overexpression of 5LO produces the oppo-
site effect in vitro: Aβ levels are elevated, and associated with
increased protein and mRNA levels of all γ-secretase proteins.
While several molecules have been linked to the regulation of
γ-secretase mRNA level, 5LO modulation occurs through the
phosphorylation of cyclic adenosine response element-binding
protein, CREB. Pharmacological inhibition of 5LO also repro-
duces 5LO knockout effects (Chu and Praticò, 2011b). Although
γ-secretase produces Aβ peptides, which are pathologic in AD,
it is also involved in the processing of Notch, a protein criti-
cal for neuronal functioning and differentiation (Imbimbo and
Giardina, 2011). Clinical trials investigating γ-secretase inhibitors
for use in AD have to date been largely unsuccessful because
they are hypothesized to have altered Notch signaling as well
as Aβ production (Doody et al., 2013). Fortunately, with 5LO
modulation, γ secretase-dependent Notch production is unper-
turbed, making any future and potential use of this class of
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drug a feasible alternative to calssical γ-secretase inhibitors.
By directly controlling the substrate availability for 5LO, FLAP
modulation similarly affects Aβ production with FLAP knock-
out and pharmacological inhibition reducing Aβ through a
CREB-mediated γ-secretase down-regulation (Chu and Praticò,
2012). In vitro data in neuronal cells have been reproduced in
mouse models of AD-like amyloidosis with similar effects of
5LO and FLAP on Aβ, which includes immunohistochemical
evidence of plaque reduction upon 5LO or FLAP knockout
(Giannopoulos et al., 2013, 2014). Recently, these data have
also been reproduced in TgCRND8 animals, with reduction
found in amyloid-associated angiopathy upon administration of
MK886, an inhibitor of FLAP (Hawkes et al., 2014). Intrigu-
ingly, leukotriene metabolites of 5LO have also been reported
to increase β- and γ-secretase-mediated generation (Wang et al.,
2013).
In addition to Aβ, 5LO and FLAP also modulate
tau phosphorylation. In cells overexpressing 5LO, tau is
hyperphosphorylated, generating both early-stage, as well as
advanced-stage tau phosphoepitopes (Chu et al., 2013). Beyond
tau phosphorylation, 5LO overexpression results in production
of paired helical filaments of tau, precursors to insoluble tau
deposition and neurofibrillary tangle formation. Knockout or
inhibition of 5LO or FLAP produces results in amelioration
of tau hyperphosphorylation (Chu and Praticò, 2013; Chu
et al., 2013). Both in vivo in murine models and in vitro, 5LO
pathway changes are mediated by 5LO and FLAP influence on
cyclin-dependent kinase 5 activity (Chu and Praticò, 2013).
As mentioned previously, abnormalities in Aβ metabolism are
presumed to be upstream of tau phosphorylation but 5LO effects
on tau phosphorylation seem to be independent of Aβ. In a series
of in vitro experiments, γ-secretase blockade in the presence of
5LO overexpression did not prevent 5LO-mediated hyperphos-
phorylation of tau (Chu et al., 2013). These in vitro results have
also been corroborated in not only a mouse model of amyloidosis
such as the Tg2576 mouse, but also a model with both Aβ and
tau pathology such as the 3xTg mouse (Chu et al., 2012b, 2013).
Beyond neuropathology, knockout of 5LO or FLAP mitigates
age-dependent AD learning and memory insults seen in two
models of AD. In both Tg2576 and 3xTg mice, 5LO knockout
or inhibition is associated with improvements in learning and
memory over baseline in fear conditioning paradigms while over-
expression of 5LO is associated with greater cognitive insult (Chu
and Praticò, 2011a; Chu et al., 2012a,b; Giannopoulos et al., 2013,
2014). Knockout or inhibition of 5LO and FLAP also ameliorates
markers of synaptic protein pathology and restores hippocampal
long-term potentiation to wild-type levels (Giannopoulos et al.,
2013, 2014). Even in aged transgenic mice, when significant
AD pathology has been deposited, targeting the 5LO pathway
appears to improve the overall AD-like phenotype (Di Meco et al.,
2014).
5LO, FLAP AND ALZHEIMER’s DISEASE-ASSOCIATED
OXIDATION AND INFLAMMATION
While 5LO and FLAP appear to reduce the cardinal pathologies
in AD, they also act on AD pathology-induced oxidative and
inflammatory insult.
In cultured rat hippocampal neurons, 5LO pathway inhibition
results in reduced Aβ-induced reactive oxygen species generation
and subsequent calcium dysregulation in a concentration-
dependent manner (Goodman et al., 1994). 5-lipoxygenase
pathway inhibition also protects against glutamate-induced exci-
totoxicity in vivo in rats, particularly in aged animals (Uz et al.,
1998). In other in vitro systems, 5LO overexpression does not
by itself lead to oxidative damage, but when overexpressed in
the presence of Aβ peptides, reduces glutathione peroxidase and
catalase levels (Wang et al., 2011b). 5-lipoxygenase pathway inhi-
bition by the pyrazole CNB-001, a 5LO-specific inhibitor, pro-
tects against endoplasmic reticulum dysfunction and proteasome
toxicity induced by Aβ both in cultured neurons as well as in
vivo (Valera et al., 2013). Interestingly, inhibition of FLAP is not
sufficient to protect against Aβ oxidative toxicity in vitro, which
suggests that even when 5LO is decoupled from Aβ metabolism,
its ability to insert molecular oxygen is preserved, retaining
pro-oxidative properties in a leukotriene-independent fashion.
However, this phenomenon is otherwise not well described or
replicated in neurons and requires further scrutiny and explo-
ration. On the other hand, leukotriene blockade has been linked
to reduction in cognitive deficits induced by traumatic brain
injury in rats, a source of oxidative stress, and a well-known risk
factor for AD (Corser-Jensen et al., 2014).
Besides oxidation, both 5LO and FLAP are active players in
the neuroinflammation found in AD. Disruption of the 5LO
pathway, either genetically or pharmacologically, reduces not
only microglia, but also astrocytosis in the brains of AD ani-
mals, seen on immunohistochemical analyses (Chu and Praticò,
2012). Moreover, with 5LO/FLAP disruption there is an associated
reduction in pro-inflammatory cytokine levels. An argument can
be made that reduction in Aβ and tau pathology caused by
5LO/FLAP inhibition independently predisposes AD transgenic
animals to have reduced neuroinflammation at baseline. While
this may be true to some extent, chronic lipopolysaccharide
administration in AD animals lacking 5LO increases steady-state
levels of γ-secretase machinery and tau phosphorylation but does
not change baseline microgliosis, astrocytosis, or brain levels of
inflammatory cytokines (Joshi et al., 2014). This line of data
suggests that the 5LO system’s contribution to the neuroinflam-
mation does not depend exclusively on Aβ or tau.
IMPLICATIONS FOR ALZHEIMER’s DISEASE THERAPY AND
BEYOND
Although several clinical trials have targeted Aβ specifically,
increasingly, their failures have lead commentators to reevaluate
not only the time course of intervention in AD, but also the
selected therapeutic targets. While tau is increasingly being recog-
nized as a viable target, and anti-oxidant and anti-inflammatory
strategies are frequently employed in studies to modify disease
course, no agent to date has been employed that independently
modulates Aβ metabolism, tau phosphorylation, oxidation and
inflammation. Although more work must be done to dissect the
mechanisms of 5LO action in model systems more advanced
than mice before considering it as a viable target, 5LO path-
way suppression has the added benefit of being safe in other
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chronic conditions such as asthma (i.e., Zileuton, Monteleukast).
Beyond AD, 5LO pathway targeting may also be useful in other
dementias and related conditions including: non-AD amyloidoses
(i.e., cerebral amyloid angiopathy), tauopathies (e.g., frontotem-
poral dementia, chronic traumatic encephalopathy, progressive
supranuclear palsy), oxidation-linked nervous system disorders
(i.e., amyotrophic lateral sclerosis) and inflammation-centered
disease processes (i.e., multiple sclerosis). Further work exploring
the 5LO system would undoubtedly shed more light on the
molecular pathways common to neurodegeneration and represent
a novel and promising platform for future drug development.
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